Navigation Links
Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Date:3/12/2009

phoblastic leukemia.
  • In September, Micromet presented the first clinical data from a phase 1b clinical trial studying the combination of adecatumumab with docetaxel in late stage metastatic breast cancer patients at the European Society for Medical Oncology in Stockholm, Sweden.
  • In August, Micromet presented the first peer-reviewed publication of clinical data on blinatumomab from the phase 1 clinical study in relapsed non-Hodgkin's lymphoma patients. These data were published in the journal Science (321: 974-977 (2008)).
  • In April, Micromet presented the first pre-clinical data on new BiTE antibodies targeting EGFR, HER-2, MCSP and CD33. In addition, data was presented from animal studies testing the subcutaneous delivery of blinatumomab and MT110.
  • Financings and related Events in 2008:

    • In December, Micromet entered into a new committed equity financing facility with Kingsbridge Capital Limited, replacing a similar facility that was established in 2006. Under the renewed facility, Kingsbridge has committed to purchase, subject to certain restrictions, limitations and conditions, up to $75 million of common stock at the time and in the amounts deemed suitable to Micromet, until December 1, 2011. Micromet is not obligated to sell to Kingsbridge any of the $75 million of common stock available under the facility, and there are no minimum commitments or minimum use penalties.
    • In November, Micromet was added to the NASDAQ Biotechnology Index.
    • In October, Micromet closed a sale of its common stock in a private placement transaction that yielded $40 million in gross proceeds.

    Program Updates in 2009:

    Consistent with its January 5, 2009, press release titled "Micromet Key Events for 2009," Micromet intends to provide an update on its research
    '/>"/>

    SOURCE Micromet, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Micromet, Inc. Reports Third Quarter 2008 Financial Results
    2. Micromet, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results
    3. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
    4. Micromet, Inc. Appoints Barclay Phillips as Senior Vice President and Chief Financial Officer
    5. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
    6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
    7. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
    8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
    9. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
    10. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/25/2014)... The report “Service Quality ... by Product Type & Provider Type - ... defines and segments the market with an ... , Browse 152 market data tables, 19 ... TOC on “Service Quality Management (SQM) and ...
    (Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... Inc. (NYSE: MDT ) has submitted ... and Drug Administration (FDA) for the use of ... system (including a newly developed catheter) for use ... delivered intravenously to patients with pulmonary arterial hypertension.   ...
    (Date:12/24/2014)... and NEW YORK , Dec. ... PTBIW), a biopharmaceutical company advancing patient care in critical ... of 3,500,000 shares of common stock, and warrants to ... stock, at an offering price of $4.00 per share ... share exercise price of $5.00, are exercisable immediately, and ...
    (Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
    Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
    ... Osteotech, Inc.,(Nasdaq: OSTE ), a leader ... medicine, announced today that the United States Patent ... U.S. Patent No.,5,676,146. The ,146 patent covers mixtures ... a radiopaque material, such as nondemineralized,or partially demineralized ...
    ... and biotechnology research companies invested a record $58.8,billion ... new life-changing,medicines and vaccines -- an increase of ... the Pharmaceutical Research and Manufacturers of,America (PhRMA) and ... coincides,with PhRMA,s 50th anniversary, which it observes today., ...
    ... China,s State Food and Drug,Administration has approved ... confocal microscope in the Peoples Republic of ... Rochester, New York-based medical device and,information company ... Lucid,s VivaScope(R) reflective confocal microscopes (RCM) ...
    Cached Biology Technology:U.S. Patent Office Confirms Validity of Osteotech's U.S. Patent No. 5,676,146 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 2R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007 3Lucid's VivaScope(R) Reflective Confocal Microscope Approved for Sale in China 2Lucid's VivaScope(R) Reflective Confocal Microscope Approved for Sale in China 3
    (Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch ... helped thousands of people to eliminate the pain of ... the antiquated system with their own biometrics fused to ... remember usernames and passwords, Hoyos Labs , the ... announced today that it is offering the app for ...
    (Date:12/22/2014)... 22, 2014  NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... consultant, Apollo Robbins for the 2015 International ... Apollo Robbins will be at ... 2015, demonstrating some of his famous theft techniques to ...
    (Date:12/22/2014)... Research and Markets ( ... the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 ... the global digital media watermarking and fingerprinting ... piracy by securely and invisibly embedding identifiable ...
    Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
    ... , Bremerhaven, 19 September 2011. Earth warming will presumably ... the South Pacific Ocean. This is the conclusion drawn ... 50-million-year-old clam shells and wood from the Antarctic. The ... also a climate rhythm over the South Pacific during ...
    ... Taiwan have confirmed a bidirectional relation between schizophrenia and ... a journal of the International League Against Epilepsy (ILAE), ... more likely to develop schizophrenia and those with schizophrenia ... epilepsy. Prior clinical studies have shown a ...
    ... have shown, for the first time in an animal, that ... parts of the central nervous system. , They subjected rainbow ... a whitening agent in many products including paints, some personal ... industry. They found that the particles caused vacuoles (holes) to ...
    Cached Biology News:50-million-year-old clam shells provide indications of future of El Nino phenomenon 2Study finds bidirectional relationship between schizophrenia and epilepsy 2
    ... Variable Speed Rocker, with 12" x 14" table; ... x 14" table; 220V. The VSR-50 Variable ... for any lab. The VSR-50 provides a rhythmic ... a gentle to vigourous movement. This makes it ...
    ...
    ...
    ...
    Biology Products: